ReviewMolecular diversity2026
Contemporary trends on the kinase inhibitors with special reference to quinoxaline derivatives.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Piperazine derivatives as anticancer agents: a medicinal chemistry review of structure, mechanism, and clinical translation.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Systems-Level Analysis of 13-Docosenamide Reveals its Regulatory Role on PPAR, AMPK, and Insulin Pathways in T2DM: In vitro and In silico Approaches.Cell biochemistry and biophysics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nitrogen-containing heterocycles owing to their unique physicochemical properties and biological effects are always of paramount importance for the development of novel class of bioactive molecules or potential lead molecules. Nitrogen containing heterocycles have tremendous potential to be developed as bioactive molecules which could inspired medicinal chemists to devise novel and greener methodologies to access them. Quinoxaline is one such valuable and indispensable scaffold having plethora of biological activities. The chemical structure of quinoxaline comprises a fused benzene and pyrazine ring. The broad spectrum of pharmacological activities of quinoxaline includes "anticancer", "antimicrobial", "antitubercular", "antiviral", "antileprotic" and "hepatoprotective". The current review, encompasses the contemporary advancements in the role of kinase and various quinoxaline based small molecule kinase inhibitors reported between 2009 and 2024 with special emphasis on their emerging mechanisms of action. The current manuscript highlights some of the recent seminal literature reports pertaining to the structural modifications carried out on quinoxaline scaffold to develop a novel anticancer agent having kinase inhibitory activity.
Indexed as
Identifiers
41417190What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.